Safety database
Regulatory status, safety summaries, calculation policy, and source summaries for the medications known to this app. Records are reference-only and must be verified against current official sources.
Reference information only
Nothing in this database is a dose recommendation. Calculation policy describes only whether the app permits arithmetic from your own clinician-provided values.
Also known as: LY3437943
- Class
- Investigational incretin receptor agonist
- Mechanism
- Investigational GIP, GLP-1, and glucagon receptor agonist
- Regulatory status
- Investigational / not FDA-approved
- Dose presets allowed in this app
- No — calculation only
Safety summary
Retatrutide is investigational and not FDA-approved. This app does not recommend retatrutide dosing. Calculations are allowed only from user-entered, clinician-provided values.
Compounding
FDA states retatrutide cannot be used in compounding under federal law.
Calculation policy
- No dose recommendations available in this app.
- Only calculation from user-entered, clinician-provided values is allowed.
- Vial-strength options are "amount of powder in the vial" values, never dosing advice.
FDA has warned about dosing errors with compounded injectable GLP-1-type products, often due to confusion between mg, mL, and syringe units. Compounded drugs are not FDA-approved; FDA does not verify their safety, effectiveness, or quality before marketing.
FDA states that retatrutide cannot be used in compounding under federal law. Retatrutide is investigational and is legally available only through Eli Lilly clinical trials.
Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist under clinical development. It is not approved by any regulatory agency.
Source summaries are provided for transparency only and may be out of date. Verify against current official sources before relying on them.